Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising results in preliminary human trials . Ongoing research suggests https://sound-social.com/story11656671/retatrutide-emerging-investigations-and-possible-therapeutic-applications